

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claims 1-31. (Canceled)

Claim 32. (Currently Amended) A method of inhibiting [[the]] IL-5, IL-3 or GM-CSF mediated proliferation of a chronic myelomonocytic cell by contacting said cell with a BION-1 monoclonal antibody or [[fragments]] a fragment thereof capable of inhibiting [[the]] binding of cytokines IL-3, GM-CSF or IL-5 to the common receptor β_c , wherein the monoclonal antibody or [[fragments]] fragment thereof binds to both the B'-C' loop and the F'-G' of domain 4 of the β_c subunit, wherein said contacting results in inhibition of IL-5, IL-3 or GM-CSF mediated proliferation of said cell.

Claim 33. (Cancelled)

Claim 34. (Currently Amended) A method of inhibiting [[the]] IL-5, IL-3 or GM-CSF mediated eosinophil activation, eosinophil production or eosinophil survival, by contacting an eosinophil with a BION-1 monoclonal antibody or [[fragments]] a fragment thereof capable of inhibiting the binding of cytokines IL-3, GM-CSF or IL-5 to the common receptor β_c , wherein the monoclonal antibody or [[fragments]] fragment thereof binds to both the B'-C' loop and the F'-G' of domain 4 of the β_c subunit, wherein said contacting results in inhibition of IL-5, IL-3 or GM-CSF mediated activation, production or survival of said eosinophil.

Claim 35-43. (Cancelled)